/ /

  • linkedin
  • Increase Font
  • Sharebar

    Micro-stent may be stand-alone option when topical glaucoma therapy fails

    Long-term results showed improved pressure control, decreased medication burden

     

    Take-Home

    Supraciliary micro-stent implantation can serve as a safe and effective stand-alone treatment in patients refractory to topical glaucoma therapy.

     

    Dr. Nguyen

    La Jolla, CA—Patients with open-angle glaucoma (OAG) whose medical therapy has failed, and who are under consideration for trabeculectomy, may find an alternative treatment in a supraciliary micro-stent (CyPass Micro-Stent, Transcend Medical) that lowers and maintains IOP over the long term.

    Implantation of the device also lowers the medication treatment burden and may preclude the need for a more invasive surgery, such as trabeculectomy or a glaucoma drainage device, said Quang H. Nguyen, MD, director of the glaucoma service, Scripps Clinic, La Jolla, CA.

    More in Special Report: Novel use of endoscope help to visualize hyphema

    To date, a number of studies of the efficacy and safety of the micro-stent have been conducted in more than 1,000 subjects worldwide. Three studies are ongoing: the DUETTE and CYCLE European studies of 65 and 500 patients, respectively, and the U.S. IDE COMPASS study of 505 patients. The 2-year follow-up data from the COMPASS study are expected in 2015.

     

    NEXT: The Duette Study

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results